Drugs / [68Ga]Ga-OncoACP3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07600554 | May 2026 → Dec 2027 expected | prostate cancer | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 1 | NCT06840535 | Apr → Oct 2025 | metastatic prostate carcinoma | Philogen S.p.A. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-OncoACP3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06840535 ↗ |
| Known as | 68Ga-OncoACP3 | “In this trial, 68Ga-OncoACP3 is offered to prostate cancer patients who already received standard of care imaging and might therefore complement available modalities.” NCT07600554 ↗ |
| Modality | Diagnostic / imaging agent | “as a PET radiotracer for the diagnostic imaging of prostate cancer” NCT06840535 ↗ |
| Route | Intravenous | “single intravenous bolus administration” NCT07600554 ↗ |
| Target | ACP3 | “OncoACP3 is a new ligand for ACP3.” NCT06840535 ↗ |